New Data Highlights Value of AI-Driven CGM-Informed Bolus Calculator
COLUMBIA, Md.–(BUSINESS WIRE)–Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced new real-world evidence (RWE) demonstrating improved time in range (TIR) through the use of Welldoc’s Continuous Glucose Monitor (CGM)-informed insulin bolus calculator.
For the millions of people who use bolus insulin, daily management is a burden. People with insulin-dependent diabetes make numerous, complex health-related decisions every day. When calculating a mealtime dose, individuals must factor in carbohydrate counts, glucose levels, CGM trend arrows, and physical activity. The stakes are high; clinical studies show that approximately 63% of manually calculated insulin doses are incorrect, often leading to hyperglycemia or dangerous hypoglycemia.1
Recently, Welldoc reviewed real-world data on the use of its CGM-informed insulin calculator and found significant improvements in glucose management over a three-month period:2
- People with elevated baseline glucose who used the calculator more than half the time improved their Time in Range (TIR) by 3.2% and Time in Tight Range (TITR) by 3.0%.
- 76% of users who utilized the calculator daily saw superior results compared to those who it used it less frequently.
“With the rapid expansion of CGM, sophisticated insulin management tools like Welldoc’s bolus calculator help patients and clinicians better manage glucose together,” said Grazia Aleppo, MD, endocrinologist at Northwestern University. “These real-world results are particularly encouraging because they demonstrate that consistent use of CGM-informed insulin calculators may lead to sustained glycemic control and a reduction in the long-term risks associated with glucose variability.”
Any improvement in TIR (the time spent with a glucose value between 70 and 180 mg/dL) above 3% has considerable clinical benefit.3 The more stringent metric, TITR, is defined as the time spent with a glucose value between 70 and 140 mg/dL. Better TITR can be achieved through more precise insulin dosing.3
“Our goal at Welldoc is to develop AI to transform complex, multivariate data into simple, actionable insights,” said Mansur Shomali, MD, endocrinologist and Chief Medical Officer at Welldoc. “These latest real-world findings validate that our calculator is a practical, effective solution, helping people with diabetes to confidently stay in range more often.”
These data build upon Welldoc’s previous multi-center clinical trial, where participants using the calculator improved TIR by 3.8% with no increase in hypoglycemia. The type 2 diabetes subgroup improved by 6.5%.4
|
1Katzlbauer K, et al. Performance of a Glucose Meter with a Built-In Automated Bolus Calculator versus Manual Bolus Calculation in Insulin-Using Subjects. J Diabetes Sci Technol. 2012;6(4):955-964. |
|
2Data on file. Welldoc, Inc., n=326 |
|
3Battelino T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. |
|
4Shomali M, et al. Safety of a Novel Continuous Glucose Monitoring–Informed Insulin Bolus Calculator Mobile Application for People With Type 1 or Type 2 Diabetes. Diabetes Spectr. 15 May 2025; 38 (2): 153–160. |
About Welldoc
Welldoc® is an AI-powered health technology leader committed to connecting people to better, more personalized cardiometabolic care. The company’s digital health platform delivers a unified experience for individuals managing diabetes, obesity (including GLP-1 support), hypertension, heart failure, and complex comorbidities including diabetes in pregnancy, sleep apnea, chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH).
The foundation of Welldoc’s solution is healthcare-ready AI, a purpose-built engine grounded in unmatched clinical rigor, with 11 FDA clearances, 60 patents, and more than 100 peer-reviewed publications demonstrating clinical effectiveness and safety. The platform’s architecture allows individuals to connect to over 400 devices and data sources, while also integrating seamlessly with electronic health record (EHR) systems, to enable comprehensive data interoperability across care settings.
Welldoc partners across multiple healthcare sectors—including life sciences companies, health plans, health systems, and employers—to drive innovative health programs, improved patient outcomes, and reduced costs at scale. The company has been recognized as a leader in healthcare innovation, named one of TIME and Statista’s World’s Top HealthTech Companies and awarded “Best Overall Digital Health Company” by MedTech Breakthrough™ for multiple consecutive years. Welldoc is strategically aligned with federal modernization efforts, including being named an early adopter in the CMS 2025 Health Tech Ecosystem Initiative. This ensures the company’s AI-powered solutions support critical programs like the CMS Rural Health Transformation Program (RHTP) focused on rural healthcare access. For more information, visit www.welldoc.com.
Contacts
Sylvia Aranda
[email protected]
